Clinical Trial Update: Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase 2/3 study of Sibeprenlimab for Immunoglobulin A nephropathy is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Sibeprenlimab

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Immunoglobulin A Nephropathy | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION